Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2013 1
2014 2
2016 1
2017 1
2018 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.
Iurlaro R, Waldhauer I, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Nicolini V, Freimoser-Grundschober A, Cuartas I, Martínez-Moreno A, Martínez-Ricarte F, Cordero E, Cicuendez M, Casalino S, Guardia-Reyes X, Fahrni L, Pöschinger T, Steinhart V, Richard M, Briner S, Mueller J, Osl F, Sam J, Colombetti S, Bacac M, Klein C, Pineda E, Reyes-Figueroa L, Di Somma A, González J, Nuciforo P, Carles J, Vieito M, Tabernero J, Umaña P, Seoane J. Iurlaro R, et al. Among authors: osl f. Mol Cancer Ther. 2022 Oct 7;21(10):1499-1509. doi: 10.1158/1535-7163.MCT-22-0201. Mol Cancer Ther. 2022. PMID: 35915983
ROCKETS - a novel one-for-all toolbox for light sheet microscopy in drug discovery.
Mueller JPJ, Dobosz M, O'Brien N, Abdoush N, Giusti AM, Lechmann M, Osl F, Wolf AK, Arellano-Viera E, Shaikh H, Sauer M, Rosenwald A, Herting F, Umaña P, Colombetti S, Pöschinger T, Beilhack A. Mueller JPJ, et al. Among authors: osl f. Front Immunol. 2023 Feb 7;14:1034032. doi: 10.3389/fimmu.2023.1034032. eCollection 2023. Front Immunol. 2023. PMID: 36845124 Free PMC article.
A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C. Castoldi R, et al. Among authors: osl f. Oncogene. 2013 Dec 12;32(50):5593-601. doi: 10.1038/onc.2013.245. Epub 2013 Jul 1. Oncogene. 2013. PMID: 23812422 Free PMC article.